Fique off-line com o app Player FM !
Ep89. Anaphylaxis myths debunked with Dr Richard Scolaro (Part 3)
Manage episode 399178375 series 2820271
This is the third and final installment of the chat I had with Immediate Past Chair of the Australian New Zealand Anaesthetic Allergy Group (ANZAAG), Dr Richard Scolaro. We discuss pholcodine and some myths about the management of anaphylaxis.
In part 1 and 2 we discuss anaesthetic anaphylaxis testing and penicillin and cephalosporin cross reactivity and more.
Register for the ASA webinar (members only) on Thursday 21st March with Dr Ben McKenzie: https://asa.org.au/amax4-every-second-counts/
ANZAAG: https://anzaag.com/
Ep.78 with Dr Ben McKenzie https://player.captivate.fm/episode/b9e24099-e5a6-49ed-ab02-1ea196c40ebd
log your CPD: https://www.cpdhome.org.au/
https://asa.org.au/events/
https://asa.org.au/types-of-membership/how-to-join/
We welcome any feedback: podcast@asa.org.au
91 episódios
Manage episode 399178375 series 2820271
This is the third and final installment of the chat I had with Immediate Past Chair of the Australian New Zealand Anaesthetic Allergy Group (ANZAAG), Dr Richard Scolaro. We discuss pholcodine and some myths about the management of anaphylaxis.
In part 1 and 2 we discuss anaesthetic anaphylaxis testing and penicillin and cephalosporin cross reactivity and more.
Register for the ASA webinar (members only) on Thursday 21st March with Dr Ben McKenzie: https://asa.org.au/amax4-every-second-counts/
ANZAAG: https://anzaag.com/
Ep.78 with Dr Ben McKenzie https://player.captivate.fm/episode/b9e24099-e5a6-49ed-ab02-1ea196c40ebd
log your CPD: https://www.cpdhome.org.au/
https://asa.org.au/events/
https://asa.org.au/types-of-membership/how-to-join/
We welcome any feedback: podcast@asa.org.au
91 episódios
Todos os episódios
×Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.